Onco Actu du 2 septembre 2015

	4. Dépistage, diagnostic et pronostic
Preventing Overdiagnosis 2015—winding back the harms of too much medicine [BMJ Blogs] Today sees the start of the third annual Preventing Overdiagnosis conference, this year hosted by the National Cancer Institute in Washington DC.
	5. Traitements
Wasp study finds sting in the tail for cancer cells [The Guardian] The venom of the Brazilian wasp Polybia paulista contains a powerful “smart” drug that selectively targets and destroys tumour cells without harming normal cells, has shown a study published in the Biophysical Journal.
	5.12 Immunothérapies
Advances in Immunotherapy: Fine-tuning CAR T Cells [CANCER RESEARCH Catalyst] Two teams tinker with the target-binding end of CAR T cells to make them safe for patients with solid tumors.
	5.2 Pharma
Ragan Reunites Ex-Genzymers at X4 Pharma to Battle Cancer [Xconomy] The plan, Ragan says, is to develop oral, small molecule drugs that target a receptor called CXC chemokine receptor type 4, or CXCR4, which is implicated in tumor progression and is overexpressed in several cancers.
Industry complains to EU over French law pushing cheap eye drug [Reuters] The move is the latest salvo in a lengthy battle between drugmakers, who argue Avastin has never been authorized for eye therapy, and cost-conscious European healthcare providers, who contend it works as well as far more costly alternatives.
	5.3 Traitements - FDA, EMA,...
Bristol-Myers and AbbVie speed toward FDA approval with a 'breakthrough' cancer drug [FierceBiotech] The antibody, elotuzumab, is designed to train the immune system's attention on a protein called SLAMF7, expressed by tumor cells that might otherwise go unnoticed by the body's natural defenses. With the priority review tag, the agency promises to give Bristol-Myers and AbbVie a final decision within 6 months, shortening the standard 10-month time frame.
EMA's medical literature monitoring enters into full operation [EMA] By reducing duplication of reporting from multiple pharmaceutical companies, the initiative will improve the safety monitoring of medicines by enhancing the quality and consistency of data reported in EudraVigilance.
	6. Lutte contre les cancers
Giant study poses DNA data-sharing dilemma [Nature News & Comment] US Precision Medicine Initiative must decide how much data to release to participants.
We have breast cancer units – so why not prostate cancer units? [ESO-The Cancer Blog] In August, the case for Europe-wide Prostate Cancer Units moves a step onwards with the publication of a new position paper from ESO in Critical Reviews in Oncology/Hematology, setting out the core criteria for defining the units in European countries.
	6.1 Observation
Two in Three Childhood Cancer Survivors Suffer Long-Term Side Effects [ACS] Two in three survivors of childhood cancer endure debilitating side effects and late effects from their cancer treatment that cause significant suffering throughout their lives, a sobering message as the nation observes Childhood Cancer Awareness Month in September.
	6.10 Politiques
To Test Cancer Sooner, we need the Government to invest in the NHS [Cancer Research UK] Today we’re launching a new campaign, to ask the Government to Test Cancer Sooner.
	6.6 Publications
Altmetrics and Research Assessment: How Not to Let History Repeat Itself [The Scholarly Kitchen] Altmetrics as they stand today are not a panacea and there is still work to be done. Now that we have the power of the web at our disposal however, it should be possible with some thought, and by learning from those who study informetrics, to continue to work towards a more complete and more useful system of research assessment.
	6.7 DMP, Big Data & applis
NIH grants seek best ways to combine genomic information and EHRs [NIH] The grants, administered by the National Human Genome Research Institute (NHGRI), represent the third phase of the eMERGE program, and focus on moving genomics research closer to clinical application by identifying the potential medical effects of rare genomic variants (inherited differences in the DNA code) in about 100 clinically relevant genes.
	6.7.2 Applis
eHealth Application to Improve Care for Cancer Patients [ESMO] Electronic Symptom Management System Remote Technology involves provision of a mobile phone where patients identify and record symptoms caused by chemotherapy.